[{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 Investigational New Drug Application for OMS906 Cleared by FDA","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Omeros"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead\u2122 Programs at the TIDES USA 2022","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Sirnaomics"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics Based on its Proprietary GalAhead\u2122 Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sirnaomics"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coagulant Therapeutics Presents Data for Severe Postpartum Hemorrhage Clinical Candidate, CT-001, at International Society for Thrombosis and Haemostasis Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Coagulant Therapeutics"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coagulant Therapeutics Announces Upcoming Oral and Poster Presentations at the 2022 American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Coagulant Therapeutics"},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"D","amount":"$412.5 million","upfrontCash":"$10.0 million","newsHeadline":"Mabwell Announces Exclusive Licensing Agreement with Disc Medicine, Inc. for Innovative Drug Candidates of Hematologic Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Mabwell"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the terms of the agreement, Disc will obtain exclusive rights to develop and commercialize 9MW3011. MWTx 01 is a recombinant monoclonal antibody targeting a key regulator in the iron homeostasis pathway, developed to treat iron overload disorders.
CT-001 is an engineered version of FVIIa that is designed to address the limitations of the recombinant FVIIa, approved for use in Hemophilia A and B patients with inhibitors, congenital FVII deficiency.
CT-001 is an engineered version of clotting factor FVIIa designed to address safety and efficacy limitations of recombinant FVIIa is approved for use in Hemophilia A and B patients with inhibitors.
STP122G is in early-stage development as an anticoagulant in settings where antithrombotic therapeutics are needed such as stroke patients and orthopedic surgery patients. STP122G targets Factor XI, a plasma glycoprotein that is primarily synthesized in the liver.
STP122G comprises RNAi triggers targeting Factor XI. Factor XI is a plasma glycoprotein that is primarily synthesized in the liver and is part of the coagulation cascade, playing a role in clot stabilization and expansion.
OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway.